

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: BM2/18 - Bone Markers

Dead line: 03.08.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(431) Parathyroid hormone (PTH)</b>					25							23	20	87%
Samples and groups	[pmol/L]													
<b>Sample A</b>		6,87	1,4	21	25							23	20	87%
(1) Immunochemical meth.; (60) Roche		6,32	0,75	12	16	0	CVPG	6,33	0,22	23%	4,87	7,79	16	
Other					9	0							7	
----- 1x 1/1, 2x 1/12, 1x 1/29, 4x 1/179, 1x 1/999 -----														
<b>Sample B</b>		23,3	4,5	19	25							23	22	96%
(1) Immunochemical meth.; (60) Roche		21,4	1,9	8,7	16	0	CVPG	21,5	0,59	23%	16,5	26,5	16	
Other					9	0							7	
----- 1x 1/1, 2x 1/12, 1x 1/29, 4x 1/179, 1x 1/999 -----														
<b>(432) Collagen telopeptide CTx-beta</b>					17							16	14	88%
Samples and groups	[ng/L]													
<b>Sample A</b>		312	27	8,7	17							16	14	88%
(1) Immunochemical meth.; (60) Roche		313	28	8,9	16	0	CVPG	323	6,3	17%	268	378	16	
Other					1	0							0	
----- 1x 1/183 -----														
<b>Sample B</b>		692	76	11	17							16	15	94%
(1) Immunochemical meth.; (60) Roche		698	72	10	16	0	CVPG	719	13	17%	596	842	16	
Other					1	0							0	
----- 1x 1/183 -----														
<b>(433) P1NP</b>					11							11	11	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		32,3	1,9	5,8	11							11	11	100%
(1) Immunochemical meth.; (60) Roche		32,3	1,9	5,8	11	0	CVPG	31,1	0,70	20%	24,8	37,4	11	
Other					11								11	11 100%
<b>Sample B</b>		184	15	8,0	11							11	11	100%
(1) Immunochemical meth.; (60) Roche		184	15	8,0	11	0	CVPG	185	4,7	20%	148	222	11	
Other														
<b>(434) Osteocalcin</b>					16							14	12	86%
Samples and groups	[µg/L]													
<b>Sample A</b>		18,4	0,95	5,1	16							14	13	93%
(1) Immunochemical meth.; (60) Roche		18,5	0,92	4,9	14	0	CVPG	18,6	0,25	13%	16,1	21,1	14	
Other					2	0							0	
----- 1x 1/24, 1x 1/29 -----														
<b>Sample B</b>		91,7	8,5	9,3	16							14	12	86%
(1) Immunochemical meth.; (60) Roche		91,6	5,6	6,2	14	0	CVPG	91,9	1,4	13%	79,9	104	14	
Other					2	0							0	
----- 1x 1/24, 1x 1/29 -----														
<b>(435) 25-hydroxyvitamin D</b>					26							24	23	96%
Samples and groups	[nmol/L]													
<b>Sample A</b>		68,3	17	25	26							24	23	96%
(1) Immunochemical meth.; (60) Roche		77,9	7,3	9,3	14	0	CVPG	79,8	2,6	33%	53,4	107	14	
(1) Immunochemical meth.; (256) Roche (2)		49,8	14	28	6	0	CVPG	45,7	4,4	33%	30,6	60,8	6	
Other					6	0							4	
----- 2x 1/1, 1x 1/12, 1x 1/149, 1x 1/164, 1x 1/999 -----														
<b>Sample B</b>		145	37	25	26							24	24	100%
(1) Immunochemical meth.; (60) Roche		165	16	9,7	14	0	CVPG	168	6,0	33%	112	224	14	
(1) Immunochemical meth.; (256) Roche (2)		114	24	21	6	0	CVPG	104	7,8	33%	69,6	139	6	
Other					6	0							4	
----- 2x 1/1, 1x 1/12, 1x 1/149, 1x 1/164, 1x 1/999 -----														

st\_kn\_p

End of report

Printed: 08.08.2018